Actively Recruiting
Study of STP938 in Advanced Solid Tumours
Led by Step Pharma, SAS · Updated on 2026-04-23
70
Participants Needed
7
Research Sites
143 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The Phase 1a part of the study is a dose escalation of STP938 as a monotherapy. The Phase 1b part of the study is a safety expansion cohort of STP938 as a monotherapy.
CONDITIONS
Official Title
Study of STP938 in Advanced Solid Tumours
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed and dated informed consent and able to follow study procedures
- Male or female aged 18 years or older
- Advanced disease not curable by available therapies and requiring systemic therapy
- Histologically confirmed diagnosis of eligible cancer type
- Availability of tumor tissue for biomarker testing
- Measurable disease (Part 1) and measurable disease per RECIST (Part 2)
- ECOG performance status of 2 or less
- Life expectancy greater than 3 months
- Adequate bone marrow, liver, kidney function, and blood clotting
- All prior cancer treatment toxicities (except hair loss) resolved to Grade 1 or baseline before enrollment
You will not qualify if you...
- Pregnant or breastfeeding females and women of childbearing potential or males unwilling to comply with contraception
- Known active or symptomatic CNS metastases, carcinomatous meningitis, leptomeningeal disease, or spinal cord compression history
- Active malignancy within 2 years prior to enrollment
- Radiation treatment within 2 weeks before starting therapy
- Systemic cancer treatments, monoclonal antibody therapies, or investigational agents within 4 weeks before enrollment or less than 5 half-lives since prior investigational therapy
- Uncontrolled intercurrent illness
- Immunocompromised with recent opportunistic infections within 12 months
- Known active or chronic hepatitis B or active hepatitis C virus infection
- Corrected QT interval over 470 msec on averaged ECG readings at screening
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Comprehensive Hematology Oncology, LLC
St. Petersburg, Florida, United States, 33709
Actively Recruiting
2
Mary Crowley Cancer Research Center
Dallas, Texas, United States, 75251
Actively Recruiting
3
Next Oncology
San Antonio, Texas, United States, 78292
Actively Recruiting
4
Institut Gustave Roussy
Villejuif, Paris, France, 94805
Actively Recruiting
5
The Beatson Institute for Cancer Research
Glasgow, Glasgow, United Kingdom, G12 8QQ
Actively Recruiting
6
University College London
London, United Kingdom
Actively Recruiting
7
The Christie
Manchester, United Kingdom, M20 4BX
Actively Recruiting
Research Team
M
Maureen Higgins
CONTACT
D
Duc Tran
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here